Compare Crispr Therapeutics AG (CRSP) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Williams-Sonoma, Inc. — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Williams-Sonoma, Inc. trades at $241.78 (market cap $28.15B). The key difference: Williams-Sonoma, Inc. is far larger — about 5.8× Crispr Therapeutics AG's market cap, and Williams-Sonoma, Inc. pays a 1.27% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Williams-Sonoma, Inc. for 59 Days on average.
| CRSP | WSM | |
|---|---|---|
Market Cap | $4.88B | $28.15B |
Volume | 2,861,747 | 1,351,262 |
Sector | Health | Consumer Cyclical |
52-Week High | $73.97 | $251.81 |
52-Week Low | $44.34 | $168.64 |
Typical Hold Time | 77 Days | 59 Days |
Enterprise Value | $3.30B | $28.65B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% on the day, reflecting a bearish technical trend amid weak financials. The company reported no revenue in 2025, with a net loss of $581.60M and negative profit margins, though it beat Q2 2026 EPS estimates. Analyst consensus remains bullish with a $67.83 price target, while recent news highlights upcoming clinical data readouts for its gene-editing therapies as potential catalysts.
The outlook hinges on pipeline execution, with key data expected by end-2026, but high cash burn and lack of revenue pose significant risks. Upside depends on successful clinical outcomes and commercialization of CASGEVY, while downside risks include trial failures and sustained losses.
Williams-Sonoma (WSM) trades at $239.00, down 0.61% on the day, with a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.10 surpassing expectations. Profitability remains robust, with a net income margin of 14.73% and ROE of 54.96%. Recent news highlights market share gains and AI integration driving growth.
The outlook is positive, supported by raised full-year guidance and strong operational execution. Key opportunities include margin expansion and dividend growth, while risks involve housing market sensitivity and competitive pressures. Analyst consensus leans bullish with a $246.31 price target, suggesting modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
